Compliance of hormone replacement therapy in menopausal women

被引:6
作者
Berenguer, IP
Genovés, JS
Cervera, JG
Bonet, SF
Polo, JMV
Mir, IM
机构
[1] Inst Social Marina, Valencia, Spain
[2] Ctr salud Nazaret, Valencia, Spain
[3] Ctr Planificac Familiar Masamagrell, Valencia, Spain
[4] Ctr Salud Sagunto, Valencia, Spain
[5] Hosp Sagunto, Valencia, Spain
[6] Hosp Gen Valencia, Valencia, Spain
来源
MEDICINA CLINICA | 2001年 / 117卷 / 06期
关键词
menopause; hormone replacement therapy; compliance;
D O I
10.1016/S0025-7753(01)72064-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The effectiveness of a given treatment is only achieved with a due compliance. Our objective was to know the compliance degree of hormone replacement therapy (HRT) in menopausal women. METHOD: A descriptive observational study was carried out in three hospitals in the Valencia Community (Spain). We included menopausal patients who were visited in a menopause unit from 1989 to 1999 and who were administered HRT. We analized age, age at menopause, type of menopause, age at starting HRT, education level, prescription reason, treatment duration, information level, side effects, and causes leading to withdrawal. RESULTS: The study was performed in 363 women. There were 75% probabilities that women fulfilled the therapy for 5 years. The median of fulfillment was 11 years. Those women who had side effects were more prone to withdraw the treatment. By contrast, women who experienced benefits were less prone to withdraw it. Risk of withdrawal was also lower in cases of postsurgery menopause and in women who were younger than 55 years when they started HRT. CONCLUSIONS: In our study, the compliance level was high and it was determined either by treatment benefits or side effects, type of menopause and age at starting HRT.
引用
收藏
页码:207 / 210
页数:4
相关论文
共 28 条
[1]  
*AG EV TECN SAN, 1995, COMPL PAT MEN
[2]   Postmenopausal hormone-replacement therapy - Time for a reappraisal? [J].
Brinton, LA ;
Schairer, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (25) :1821-1822
[3]  
*C CONS, 1995, PROY OBSTET GIN, V38, P3
[4]   COMPLIANCE TO HORMONE REPLACEMENT THERAPY IN MENOPAUSAL WOMEN CONTROLLED IN A 3RD LEVEL ACADEMIC CENTER [J].
CANO, A .
MATURITAS, 1994, 20 (2-3) :91-99
[5]   Patient-specific decisions about hormone replacement therapy in postmenopausal women [J].
Col, NF ;
Eckman, MH ;
Karas, RH ;
Pauker, SG ;
Goldberg, RJ ;
Ross, EM ;
Orr, RK ;
Wong, JB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (14) :1140-1147
[6]   Determinants of long-term hormone replacement therapy and reasons for early discontinuation [J].
Den Tonkelaar, I ;
Oddens, BJ .
OBSTETRICS AND GYNECOLOGY, 2000, 95 (04) :507-512
[7]  
Doren M, 1996, INT J FERTIL MENOP S, V41, P29
[8]   SUPERIOR COMPLIANCE AND EFFICACY OF CONTINUOUS COMBINED ORAL ESTROGEN-PROGESTOGEN REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN [J].
DOREN, M ;
REUTHER, G ;
MINNE, HW ;
SCHNEIDER, HPG .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 173 (05) :1446-1451
[9]  
DURAN JA, 1988, MED CLIN-BARCELONA, V90, P338
[10]   COMPLIANCE WITH LONG-TERM ORAL HORMONAL REPLACEMENT THERAPY [J].
EIKEN, P ;
KOLTHOFF, N .
MATURITAS, 1995, 22 (02) :97-103